FDA 483 - Andrew C. Siesennop, MD - August 04, 2023

An FDA inspection of Andrew C. Siesennop, MD in Boston, MA, revealed a significant issue with the conduct of an investigational study. The firm failed to follow its investigational plan, resulting in three subjects being incorrectly dosed with the study drug. This indicates a deviation from proper clinical trial procedures.